This trial is investigating a new drug, FOR46, that targets CD46 in prostate cancer. CD46 is a protein that is found on the surface of many types of cells, and is particularly common in adenocarcinoma and Small-cell neuroendocrine carcinoma (SCNC), which are two aggressive and deadly forms of prostate cancer. The goal of the trial is to see if FOR46 can be used to treat these aggressive forms of prostate cancer, and to help develop new treatments that improve outcomes for men with these types of cancer.
5 Primary · 7 Secondary · Reporting Duration: Up to 24 months
24 Total Participants · 3 Treatment Groups
Primary Treatment: 89Zr-DFO-YS5 · No Placebo Group · Phase 1
Age 18+ · All Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you: